A Phase 3 interventional study of Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg) and Standard medical treatment in Acute Ischemic Stroke, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing tenecteplase in Ischemic Stroke — 32 open to participants now, 32 under way, 25 of them phase 3. Tenecteplase · Ischemic Stroke.
Among the 59 studies testing tenecteplase in Ischemic Stroke, this one is the 19th largest by planned enrollment, is one of 11 that started in 2026, is one of 37 in phase 3, reaches primary completion later than 22 of the 31 other live ones, and was the 54th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →32 of the 59 studies testing tenecteplase in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Zhengzhou University · Sites in China
Ages 18+
Yongjun Wang · Sites in China
Ages 18+
Shandong Provincial Hospital · Sites in China
Ages 18+
First Affiliated Hospital of Guangxi Medical University · Sites in China
Ages 18+
General Hospital of Shenyang Military Region · Sites in China
Ages 18–80
By country, each count listing its studies:
Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 16 · Phase 3 43 · Phase 4 5
First in 2012; this study’s year is marked. 11 started in 2026.
This study's planned enrollment of 750 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 466 across the 59 interventional studies. Of the 22 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 59 have an industry lead sponsor. The 10 most frequent:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 485 studies on the registry; 279 are open to participants now.
13 studies in Ischemic Stroke by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University: 11 open now, 11 under way, 5 of them phase 3. Of 2 finished, 0 (0%) have results posted.
Among the 13 studies in Ischemic Stroke by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, this one is one of 3 that started in 2026, is one of 6 in phase 3, reaches primary completion later than 3 of the 10 other live ones, and was the 13th registered.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University’s Ischemic Stroke studies by the year they started, since 2017.
7 of the studies testing tenecteplase in Ischemic Stroke that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
| NCT07047014Phase 3Beijing Tiantan HospitalAdvancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke | 2027-03-30 |
| NCT07073469Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityTenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial | 2027-08-01 |
| NCT07201688Phase 3CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window. | 2027-09-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 59 studies testing tenecteplase in Ischemic Stroke, from their registry updates:
Among Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University’s 13 in Ischemic Stroke:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The PEARL-SIMPLIFIED trial is a multicenter, prospective, randomized controlled, open-label, blinded-endpoint study. It aims to evaluate the efficacy and safety of intravenous tenecteplase (TNK) in patients with acute ischemic stroke (AIS) presenting in the extended 4.5-24 hour window, using a simplified imaging selection strategy based solely on non-contrast CT (NCCT).
The PEARL-SIMPLIFIED trial is a multicenter, prospective, randomized controlled, open-label, blinded-endpoint study with a target enrollment of at least 750 patients. The trial focuses on individuals with acute ischemic stroke (AIS) presenting within a 4.5 to 24-hour window who are not planned for endovascular thrombectomy (EVT). Patients meeting simplified imaging criteria based on non-contrast CT (NCCT) are randomized 1:1 to receive a single intravenous bolus of 0.25 mg/kg tenecteplase (TNK) or standard medical treatment. The primary outcome is the 90-day excellent functional outcome, defined as a modified Rankin Scale (mRS) score of 0-1. Safety outcomes include symptomatic intracranial hemorrhage (sICH) and 90-day mortality.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous tenecteplase
Drug: Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg)
Standard medical treatment
Drug: Standard medical treatment
Drug page: TenecteplaseStudies of TenecteplaseTenecteplase pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Patients randomized to the intervention arm will receive tenecteplase via a single intravenous bolus (0.25 mg/kg; maximum dose 25 mg), administered immediately following randomization.
Patients in the control arm will receive standard medical treatment.
Excellent functional outcome
The proportion of mRS score 0-1 at 90 (±14) days.
Time frame: at 90 (±14) days
Ordinal distribution of mRS
The proportion of mRS distribution at 90 (±14) days
Time frame: at 90 (±14) days
Favorable functional outcome
The proportion of mRS score 0-2 at 90 (±14) days
Time frame: at 90 (±14) days
Change in NIHSS Score at 24 (±12) hours
NIHSS score change from baseline at 24 (±12) hours
Time frame: at 24 (±12) hours
Change in NIHSS Score at 7 (±1) days or discharge
NIHSS score change from baseline at 7 (±1) days or discharge
Time frame: at 7 (±1) days or discharge
Quality of life (EQ-5D-5L)
Quality of life measured by EQ-5D-5L at 90 (±14) days
Time frame: at 90 (±14) days
Symptomatic intracranial hemorrhage
Symptomatic intracranial hemorrhage (sICH) within 36 hours from randomization (SITS-MOST criteria)
Time frame: within 36 hours
Any intracranial hemorrhage
Any intracranial hemorrhage within 36 hours
Time frame: within 36 hours
Major extracranial bleeding
Major extracranial bleeding within 36 hours (GUSTO criteria: moderate and severe bleeding)
Time frame: within 36 hours
Mortality
All-cause mortality within 90 days
Time frame: within 90 days
Plan to share: Yes — The IPD will be available from the Principal Investigator upon reasonable request 6 months after the trial completion.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: 6 months after the trial completion.
Access criteria: The IPD will be available from the Principal Investigator upon reasonable request 6 months after the trial completion.
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Dec 2028, 28 months later.
Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 28 months is below that.
Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenecteplase
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University →